Tumor News and Research

RSS

Study identifies MDM4 protein as promising target for treatment of melanoma

A melanoma is a malignant form of skin cancer and is one of the most aggressive types of tumors there is. Treatment is particularly difficult, because melanomas are usually resistant against conventional chemotherapy treatments.

24 Jul 2012

Stromal cells offer chemotherapy clue in early lung cancer

Podoplanin-positive cancer-associated fibroblasts predict recurrence in stage I lung adenocarcinoma, which could help identify patients suited for adjuvant chemotherapy, research shows.

24 Jul 2012

OncoSec announces data from two Phase III trials of OMS ElectroChemotherapy for SCCHN

OncoSec Medical Inc., a company developing the advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumors, announced data from an interim analysis of two randomized Phase III clinical trials, HNBE-01 and HNBE-02, using electrochemotherapy to treat locally recurrent and second primary squamous cell carcinoma of the head and neck.

24 Jul 2012

Tumor necrosis factor may play a key role in how light at night leads to depression

Chronic exposure to dim light at night can lead to depressive symptoms in rodents -- but these negative effects can be reversed simply by returning to a standard light-dark cycle, a new study suggests.

24 Jul 2012

New laser technology can non-invasively destruct cancerous tumors

Researchers at the Center for Laser Applications at the University of Tennessee Space Institute in Tullahoma have developed a technology that goes on a "seek and destroy" mission for cancerous tumors. They have harnessed the power of lasers to find, map and non-invasively destruct cancerous tumors.

24 Jul 2012

Bioniche receives U.S. and Canadian approval for first of two canine oncology products

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced that the first of two canine oncology products has received approval by regulators in both the U.S. and Canada.

24 Jul 2012

Neural precursor cells suppress aggressive tumors

Neural precursor cells (NPC) in the young brain suppress certain brain tumors such as high-grade gliomas, especially glioblastoma (GBM), which are among the most common and most aggressive tumors.

23 Jul 2012

Berg Pharma initiates BPM 31543 clinical trial for chemotherapy-induced alopecia

Berg Pharma, a Boston-based pharmaceutical company focused on discovery and development of new treatments in cancer and metabolic diseases, announced the initiation of a clinical trial entitled "Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a Topical Compound 31543 in Adult Patients Receiving Chemotherapy for the Treatment of Breast Cancer."

23 Jul 2012

Novel genomic sequencing method can help conduct in-depth analysis of single cells

Only by viewing a Georges Seurat painting at close range can you appreciate the hidden complexities of pointillism - small, distinct dots of color applied to form an image from a distance. Similarly, biologists and geneticists have long sought to analyze profiles of genes at the single cell level but technology limitations have only allowed a view from afar.

23 Jul 2012

Cerulean commences dosing in CRLX101 Phase 2 study for ovarian cancer

Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in a Phase 2 study of its lead candidate, CRLX101, in platinum-resistant ovarian cancer patients.

23 Jul 2012

NSCLC survival increase 'an artifact of PET assessment'

There has been no increase in survival among non-small-cell lung cancer patients in recent years, with evidence suggesting otherwise likely due to positron emission tomography-induced stage migration and selection bias, say US scientists.

23 Jul 2012

Fat grafts ‘safe’ following breast reconstruction

Autologous fat grafting following breast reconstruction does not increase the long-term risk for tumor recurrence, US research shows.

23 Jul 2012

Researchers identify several gene mutations responsible for medulloblastoma

Researchers at the Stanford University School of Medicine and Lucile Packard Children's Hospital have identified several gene mutations responsible for the most common childhood brain tumor, called medulloblastoma, adding evidence to the theory that the diagnosis is a group of genetically distinct cancers with different prognoses. These and accompanying findings are likely to lead to less-toxic, better-targeted treatment approaches over the next two years, the researchers said.

23 Jul 2012

Study: HIV-infected women less likely to develop cervical cancer

HIV-infected and uninfected women with normal cervical cytology (Pap test) and a negative test result for oncogenic (tumor inducing) human papillomavirus DNA at study enrollment had a similar risk of cervical precancer and cancer after 5 years of follow-up, according to a study in the July 25 issue of JAMA, a theme issue on HIV/AIDS.

23 Jul 2012

Researchers link specific gene mutations with four recognized subtypes of medulloblastoma

Researchers at Dana-Farber/Children's Hospital Cancer Center (DF/CHCC) and several collaborating institutions have linked mutations in specific genes to each of the four recognized subtypes of medulloblastoma, the most common malignant brain tumor of children. The discovery, reported July in the journal Nature, provides doctors with potential biomarkers for guiding and individualizing treatment and reveals prospective therapeutic opportunities for countering this devastating malignancy.

23 Jul 2012

Kyprolis for multiple myeloma receives FDA approval under accelerated approval program

The U.S. Food and Drug Administration today approved Kyprolis (carfilzomib) to treat patients with multiple myeloma who have received at least two prior therapies, including treatment with Velcade (bortezomib) and an immunomodulatory therapy. A form of blood cancer that arises from plasma cells, multiple myeloma usually grows in bone marrow, the soft, spongy tissue found inside most bones.

21 Jul 2012

FDA grants accelerated approval for Kyprolis to treat multiple myeloma

Ligand Pharmaceuticals Incorporated today announced that its licensee, Onyx Pharmaceuticals, received accelerated approval from the U.S. Food and Drug Administration (FDA) for Kyprolis (carfilzomib) for Injection, a proteasome inhibitor indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.

21 Jul 2012

2-D models may often give researchers misleading results

Imagine millions of cancer cells organized in thousands of small divots. Hit these cells with drugs and when some cells die, you have a candidate for a cancer drug. But a review published this week in the journal Expert Opinion on Drug Discovery argues that these 2D models in fact offer very little information about a potential drug's effects in the body and may often give researchers misleading results.

21 Jul 2012

Researchers discover reason why breast cancer cells become drug resistant

Breast cancer treatments such as Herceptin that target a marker called HER2 have dramatically improved outcomes for women with this type of cancer. But nearly half of these cancers are resistant to Herceptin from the start and almost all of them will eventually become resistant.

21 Jul 2012

FDA grants accelerated approval to Onyx's Kyprolis for treatment of multiple myeloma

Onyx Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Kyprolis (carfilzomib) for Injection, a proteasome inhibitor, indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.

21 Jul 2012

Tumor News and Research

Study identifies MDM4 protein as promising target for treatment of melanoma

Stromal cells offer chemotherapy clue in early lung cancer

OncoSec announces data from two Phase III trials of OMS ElectroChemotherapy for SCCHN

Tumor necrosis factor may play a key role in how light at night leads to depression

New laser technology can non-invasively destruct cancerous tumors

Bioniche receives U.S. and Canadian approval for first of two canine oncology products

Neural precursor cells suppress aggressive tumors

Berg Pharma initiates BPM 31543 clinical trial for chemotherapy-induced alopecia

Novel genomic sequencing method can help conduct in-depth analysis of single cells

Cerulean commences dosing in CRLX101 Phase 2 study for ovarian cancer

NSCLC survival increase 'an artifact of PET assessment'

Fat grafts ‘safe’ following breast reconstruction

Researchers identify several gene mutations responsible for medulloblastoma

Study: HIV-infected women less likely to develop cervical cancer

Researchers link specific gene mutations with four recognized subtypes of medulloblastoma

Kyprolis for multiple myeloma receives FDA approval under accelerated approval program

FDA grants accelerated approval for Kyprolis to treat multiple myeloma

2-D models may often give researchers misleading results

Researchers discover reason why breast cancer cells become drug resistant

FDA grants accelerated approval to Onyx's Kyprolis for treatment of multiple myeloma

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News